C&L: Klemm named CEO of Predictive Biosciences

Predictive Biosciences has named Peter Klemm, Ph.D., as the company's first president and chief executive officer.

Juvaris BioTherapeutics hired Grant Pickering as its new CEO, replacing Martin Cleary. Cleary will remain chairman of the board at the company.

Isolagen has promoted Vice President and Corporate Controller Todd Greenspan to the post of chief financial officer. Senior Director of Operations John Maslowski has been promoted to vice president of operations.

Barrier Therapeutics has appointed Dennis P. Reilly chief financial officer.

Ipsen has named Frederic Babin as executive vice-president, human resources and member of Ipsen's executive committee.

Cytomedix has named Martin P. Rosendale executive vice president and chief operating officer.

SYGNIS Pharma AG has appointed Dr. Frank Rathgeb to the newly created position of chief medical officer.

Phase Forward has appointed Russell J. Campanello as senior vice president, human resources and administration.

NuGEN Technologies has hired Dr. Beth Ladin to serve as the company's vice president of operations.

Organogenesis has hired Damien Bates, MD, PhD, FRACS (Plast.), as vice president of medical affairs.

Michael Rochelle has joined QuoNova as vice president of strategic marketing and business development. Jim Walls is the new VP Product Development for QuoNova. Mohamed Baccouche has joined as VP of regulatory affairs and is based in uoNova's office in Germany.

Array BioPharma has hired Gary Clark, Ph.D., as vice president of biostatistics and data management.

Dyadic International has elected Wendell Adair, Jr., to the board of directors. Adair replaces Richard Berman, who has resigned.

Vaxart announced that Robert Fildes, PhD, has been appointed to the board of directors.

Proteon Therapeutics has appointed Gregory Phelps to the company's board of directors.

Immunosyn Corporation named Myron Wentz, Ph.D., to its board of directors.

George Butler has been appointed to the board of Bionovo.

Sepracor announced that board member James Andress has died. 

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.